IL302769A - History of cyclopentathiophene carboxamide as platelet-activating factor receptor antagonists - Google Patents
History of cyclopentathiophene carboxamide as platelet-activating factor receptor antagonistsInfo
- Publication number
- IL302769A IL302769A IL302769A IL30276923A IL302769A IL 302769 A IL302769 A IL 302769A IL 302769 A IL302769 A IL 302769A IL 30276923 A IL30276923 A IL 30276923A IL 302769 A IL302769 A IL 302769A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- optionally substituted
- group
- methyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 | ||
| PCT/EP2021/081459 WO2022101377A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302769A true IL302769A (en) | 2023-07-01 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302769A IL302769A (en) | 2020-11-16 | 2021-11-12 | History of cyclopentathiophene carboxamide as platelet-activating factor receptor antagonists |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (enExample) |
| EP (1) | EP4244229A1 (enExample) |
| JP (3) | JP7465368B2 (enExample) |
| KR (1) | KR20230109692A (enExample) |
| CN (2) | CN116745300A (enExample) |
| AR (1) | AR124070A1 (enExample) |
| AU (1) | AU2021379248A1 (enExample) |
| CA (1) | CA3200710A1 (enExample) |
| CL (2) | CL2023001361A1 (enExample) |
| CO (1) | CO2023005894A2 (enExample) |
| CR (2) | CR20230211A (enExample) |
| DO (1) | DOP2023000090A (enExample) |
| EC (1) | ECSP23036210A (enExample) |
| IL (1) | IL302769A (enExample) |
| JO (1) | JOP20230107A1 (enExample) |
| MX (1) | MX2023005678A (enExample) |
| PE (1) | PE20231855A1 (enExample) |
| SA (1) | SA523440809B1 (enExample) |
| TW (1) | TWI913356B (enExample) |
| WO (1) | WO2022101377A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119842821A (zh) * | 2025-01-06 | 2025-04-18 | 华中科技大学 | 稳定表达血小板活化因子受体的细胞株、构建方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| DD265405A5 (de) * | 1986-01-21 | 1989-03-01 | Boehringer Ingelheim Kg,De | Neue thieno-1,4-diazepine |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| MC1999A1 (fr) * | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
| US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| JP2959598B2 (ja) | 1990-10-12 | 1999-10-06 | 吉富製薬株式会社 | 光学活性なチエノトリアゾロジアゼピン化合物 |
| CN1033327C (zh) | 1991-04-23 | 1996-11-20 | 东丽株式会社 | 三环三唑并衍生物的制造方法 |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| US7749996B2 (en) | 2006-11-20 | 2010-07-06 | Alantos Pharmaceutical Holdings, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko active Pending
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en not_active Ceased
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 PE PE2023001605A patent/PE20231855A1/es unknown
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 CN CN202311341729.0A patent/CN117624188B/zh active Active
- 2021-11-12 CR CR20260053A patent/CR20260053A/es unknown
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
- 2021-11-15 TW TW110142333A patent/TWI913356B/zh active
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-16 JO JOJO/P/2023/0107A patent/JOP20230107A1/ar unknown
- 2023-05-16 SA SA523440809A patent/SA523440809B1/ar unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
-
2024
- 2024-02-01 CL CL2024000317A patent/CL2024000317A1/es unknown
- 2024-03-29 JP JP2024055696A patent/JP7810743B2/ja active Active
-
2026
- 2026-01-22 JP JP2026008915A patent/JP2026090284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160725A1 (en) | 2022-05-26 |
| CL2024000317A1 (es) | 2024-07-12 |
| AU2021379248A1 (en) | 2023-06-22 |
| TW202237620A (zh) | 2022-10-01 |
| CN117624188B (zh) | 2026-08-07 |
| JP7465368B2 (ja) | 2024-04-10 |
| CN117624188A (zh) | 2024-03-01 |
| PE20231855A1 (es) | 2023-11-21 |
| DOP2023000090A (es) | 2023-06-15 |
| JP7810743B2 (ja) | 2026-02-03 |
| CA3200710A1 (en) | 2022-05-19 |
| CO2023005894A2 (es) | 2023-05-29 |
| EP4244229A1 (en) | 2023-09-20 |
| CN116745300A (zh) | 2023-09-12 |
| JP2026090284A (ja) | 2026-06-02 |
| AU2021379248A9 (en) | 2024-10-10 |
| US11766443B2 (en) | 2023-09-26 |
| JP2023521200A (ja) | 2023-05-23 |
| ECSP23036210A (es) | 2023-06-30 |
| CR20230211A (es) | 2023-07-13 |
| SA523440809B1 (ar) | 2024-10-08 |
| WO2022101377A1 (en) | 2022-05-19 |
| US20230355638A1 (en) | 2023-11-09 |
| JOP20230107A1 (ar) | 2023-05-16 |
| KR20230109692A (ko) | 2023-07-20 |
| TWI913356B (zh) | 2026-02-01 |
| CL2023001361A1 (es) | 2023-11-03 |
| MX2023005678A (es) | 2023-05-26 |
| CR20260053A (es) | 2026-03-24 |
| JP2024099528A (ja) | 2024-07-25 |
| AR124070A1 (es) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112778276B (zh) | 作为shp2抑制剂的化合物及其应用 | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| KR20190026904A (ko) | 비시클릭 헤테로아릴 치환된 화합물 | |
| WO2014101295A2 (zh) | 一种詹纳斯激酶（JAKs）抑制活性的异恶唑衍生物 | |
| TW202421130A (zh) | 作為pi3k抑制劑的異喹啉酮 | |
| JP2025500886A (ja) | 大環状ｂｔｋ阻害剤 | |
| CA3106513A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| TW202021586A (zh) | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 | |
| JP2021513530A (ja) | テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用 | |
| WO2020116662A1 (ja) | シクロアルカン−１，３−ジアミン誘導体 | |
| CA3140017A1 (en) | Polyaromatic urea derivatives and their use in the treatment of muscle diseases | |
| EP2513108B1 (fr) | NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| WO2021160718A1 (en) | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | |
| KR20250030448A (ko) | Pi3k 억제제로서의 벤조피리미딘-4(3h)-온 | |
| KR20240168922A (ko) | 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도 | |
| JP7810743B2 (ja) | 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 | |
| EP3863713B1 (en) | Phenyltetrazole derivatives as plasma kallikrein inhibitors | |
| US11992494B2 (en) | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | |
| EA048242B1 (ru) | Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов | |
| RU2800292C2 (ru) | Химические соединения | |
| CA3269027A1 (en) | Azole derivatives as shp2 inhibitors | |
| CA3174252A1 (en) | Compounds active towards nuclear receptors |